213 related articles for article (PubMed ID: 11982953)
21. Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells.
Morawietz H; Goettsch W; Brux M; Reimann M; Bornstein SR; Julius U; Ziemssen T
Atheroscler Suppl; 2013 Jan; 14(1):107-13. PubMed ID: 23357151
[TBL] [Abstract][Full Text] [Related]
22. Direct adsorption of low-density lipoprotein by DALI-LDL-apheresis: results of a prospective long-term multicenter follow-up covering 12,291 sessions.
Bosch T; Gahr S; Belschner U; Schaefer C; Lennertz A; Rammo J;
Ther Apher Dial; 2006 Jun; 10(3):210-8. PubMed ID: 16817783
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of DALI-LDL-apheresis in two patients treated with the angiotensin II-receptor 1 antagonist losartan.
Bosch T; Wendler T
Ther Apher Dial; 2004 Aug; 8(4):269-74. PubMed ID: 15274676
[TBL] [Abstract][Full Text] [Related]
24. LDL hemoperfusion--a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood.
Bosch T; Schmidt B; Kleophas W; Gillen C; Otto V; Passlick-Deetjen J; Gurland HJ
Artif Organs; 1997 Sep; 21(9):977-82. PubMed ID: 9288867
[TBL] [Abstract][Full Text] [Related]
25. Effects of lipoprotein apheresis on PCSK9 levels.
Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
[TBL] [Abstract][Full Text] [Related]
26. DALI-the first human whole-blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results.
Dräger LJ; Julius U; Kraenzle K; Schaper J; Toepfer M; Zygan K; Otto V; Steinhagen-Thiessen E
Eur J Clin Invest; 1998 Dec; 28(12):994-1002. PubMed ID: 9893010
[TBL] [Abstract][Full Text] [Related]
27. Modified DALI LDL-apheresis using trisodium citrate anticoagulation plus bicarbonate or lactate-buffered hemofiltration substitution fluids as primers.
Bosch T; Wendler T; Maschke H
Artif Organs; 2003 Jun; 27(6):555-64. PubMed ID: 12780510
[TBL] [Abstract][Full Text] [Related]
28. Long-term therapeutic efficacy of lipoprotein apheresis on circulating oxidative stress parameters--A comparison of two different apheresis techniques.
Kopprasch S; Bornstein SR; Bergmann S; Graessler J; Julius U
Atheroscler Suppl; 2015 May; 18():80-4. PubMed ID: 25936309
[TBL] [Abstract][Full Text] [Related]
29. Low density lipoprotein hemoperfusion by direct adsorption of lipoproteins from whole blood (DALI apheresis): clinical experience from a single center.
Bosch T; Lennertz A; Kordes B; Samtleben W
Ther Apher; 1999 Aug; 3(3):209-13. PubMed ID: 10427617
[TBL] [Abstract][Full Text] [Related]
30. How to optimize lipoprotein apheresis treatment--a second look.
Schettler V; Neumann CL; Hagenah GC; Schulz EG; Wieland E
Atheroscler Suppl; 2013 Jan; 14(1):89-92. PubMed ID: 23357148
[TBL] [Abstract][Full Text] [Related]
31. Long-term reduction of C-reactive protein concentration by regular LDL apheresis.
Otto C; Geiss HC; Empen K; Parhofer KG
Atherosclerosis; 2004 May; 174(1):151-6. PubMed ID: 15135264
[TBL] [Abstract][Full Text] [Related]
32. Practical aspects of direct adsorption of lipoproteins from whole blood by DALI LDL-apheresis.
Bosch T
Transfus Apher Sci; 2004 Oct; 31(2):83-8. PubMed ID: 15501411
[TBL] [Abstract][Full Text] [Related]
33. Effects of LDL apheresis on blood rheology in two patients with homozygous familial hypercholesterolaemia.
Fadul JE; Sandhagen B; Linde T; Vessby B; Wikström B; Danielson BG
Blood Purif; 1997; 15(3):182-7. PubMed ID: 9262844
[TBL] [Abstract][Full Text] [Related]
34. Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresis.
Bräutigam C; Engelmann B; Reiss D; Reinhardt U; Thiery J; Richter WO; Brosche T
Atherosclerosis; 1996 Jan; 119(1):77-88. PubMed ID: 8929259
[TBL] [Abstract][Full Text] [Related]
35. Effect of low-dose citrate anticoagulation on the clinical safety and efficacy of direct adsorption of lipoproteins (DALI apheresis) in hypercholesterolemic patients: a prospective controlled clinical trial.
Bosch T; Heinemann O; Duhr C; Wendler T; Keller C; Fink E; Kirschner T; Klebert S; Samtleben W
Artif Organs; 2000 Oct; 24(10):790-6. PubMed ID: 11091168
[TBL] [Abstract][Full Text] [Related]
36. Effect of low-density lipoprotein apheresis on plasma levels of apolipoprotein e4.
Moriarty PM; Luyendyk JP; Gibson CA; Backes JM
Am J Cardiol; 2010 Jun; 105(11):1585-7. PubMed ID: 20494666
[TBL] [Abstract][Full Text] [Related]
37. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins.
Geiss HC; Otto C; Hund-Wissner E; Parhofer KG
Atherosclerosis; 2005 May; 180(1):107-12. PubMed ID: 15823282
[TBL] [Abstract][Full Text] [Related]
38. Comparative analysis between dextran sulfate adsorption and direct adsorption of lipoproteins in their capability to reduce erythrocyte adhesiveness/aggregation in the peripheral blood.
Schechner V; Berliner S; Shapira I; Justo D; Hershcovici T; Zeltser D; Beigel Y
Ther Apher Dial; 2004 Feb; 8(1):39-44. PubMed ID: 15128018
[TBL] [Abstract][Full Text] [Related]
39. State of the art of low-density lipoprotein apheresis in the year 2003.
Bosch T; Wendler T
Ther Apher Dial; 2004 Apr; 8(2):76-9. PubMed ID: 15255120
[TBL] [Abstract][Full Text] [Related]
40. Single LDL apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects.
Kobayashi J; Katsube S; Shimoda M; Furuhashi K; Kitano S; Masuda M; Maruyama T; Shinomiya M
Clin Chim Acta; 2002 Jul; 321(1-2):107-12. PubMed ID: 12031599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
